BioMed Nexus Update: Feb 14 News & Tools

Daily Market Analysis

FDA’s Stunning uniQure Reversal Triggers 49% Plunge, While Phio’s Tumor Data and Krystal’s Q3 Beat Highlight Biotech’s Extremes

Biotech opened the week navigating extreme regulatory volatility and clinical performance divergence. uniQure suffered a devastating 49% share collapse after the FDA reversed course on its Huntington’s disease gene therapy, ruling previously encouraged data insufficient for accelerated approval consideration. Meanwhile, Phio Pharmaceuticals soared 21% on

Daily Updates

Biotech’s Mega-Deal Monday: Novartis’ $12B Avidity Buy, Novo-Pfizer Obesity War, and AI Partnerships Reshape the Sector

Healthcare markets exploded with deal-making activity as November opened with a bang. Novartis dropped $12 billion to acquire Avidity Biosciences, Novo Nordisk and Pfizer escalated their obesity bidding war for Metsera to $9 billion (culminating in a lawsuit), and AI partnerships dominated headlines as Roche

Daily Updates

Halloween Week Biotech Shakeup: Intellia CRISPR Hold, FDA Biosimilar Revolution, and Metabolic M&A Frenzy

Biotech delivered a sobering Halloween eve session as regulatory concerns collided with policy reforms and M&A speculation. Intellia Therapeutics’ CRISPR programs hit an FDA clinical hold following a serious adverse event, sending ripples through the gene-editing sector and raising fundamental questions about the safety of

BioMed Nexus Update: Feb 14 News & Tools

Table of Contents

Featured Articles

FDA’s Stunning uniQure Reversal Triggers 49% Plunge, While Phio’s Tumor Data and Krystal’s Q3 Beat Highlight Biotech’s Extremes

Biotech’s Mega-Deal Monday: Novartis’ $12B Avidity Buy, Novo-Pfizer Obesity War, and AI Partnerships Reshape the Sector

Halloween Week Biotech Shakeup: Intellia CRISPR Hold, FDA Biosimilar Revolution, and Metabolic M&A Frenzy

BioMed Nexus Update: Feb 14 News & Tools

Table of Contents

Featured Articles

FDA’s Stunning uniQure Reversal Triggers 49% Plunge, While Phio’s Tumor Data and Krystal’s Q3 Beat Highlight Biotech’s Extremes

Biotech’s Mega-Deal Monday: Novartis’ $12B Avidity Buy, Novo-Pfizer Obesity War, and AI Partnerships Reshape the Sector

Halloween Week Biotech Shakeup: Intellia CRISPR Hold, FDA Biosimilar Revolution, and Metabolic M&A Frenzy

Join a Community of 35,000+ Industry Leaders and Innovators

Stay Ahead in Biotech & MedTech Innovations

Join the BioMed Nexus community and get the latest breakthroughs, research updates, and industry insights delivered straight to your inbox.